Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Market Cap	$154.29M	P/E Ratio	5.46
52W High	$5.01	52W Low	$1.98
Div Yield	25.0%	Payout Ratio	9.6%
EPS Growth 3Y	17.6%	52W Position	62.8%
Overall Score	58	Value Score	80
Quality Score	44	Technical Score	50

EPS Current Est	$0.71	EPS Next Est	$NA
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ORMP	$3.88	+2.37%	149.67K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ORMP	$3.88	+2.4%	149.67K
3
4
5
6

ORMP

ORMP

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Oramed Pharmaceuticals Inc. Data in Excel

Get Oramed Pharmaceuticals Inc. Data in Excel